AstraZeneca said on March 24 the company’s drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening.
https://www.pharmalive.com/wp-content/uploads/2022/03/AstraZenecas-Imfinzi-fails-main-goal-in-advanced-cervical-cancer-study-Reuters-3-24-22.jpg6281200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-03-24 04:28:342022-03-24 10:45:11AstraZeneca’s Imfinzi fails main goal in advanced cervical cancer study